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Antimicrobial resistance (AMR) is not a recent 
phenomenon, but it is a critical health issue 
today. Over several decades, to varying 
degrees, bacteria causing common infections 
have developed resistance to each new 
antibiotic and AMR has evolved to become a 
worldwide health threat. With a dearth of new 
antibiotics coming to market, the need for 
action to avert a developing global crisis in 
health care is increasingly urgent (WHO, 20
The rising prevalence of multidrug
bacteria has emerged as one of the greatest 
challenges to quality healthcare delivery with a 
greater burden on developing nations, 
accounting for a large proportion of hospital
acquired infections (Conen et al., 2015; 




This study was carried out to determine the antibiotic susceptibility profile of Gram 
negative bacteria obtained from three different hospitals for class D Oxa β
Kano metropolis. The clinical isolates include: Escherichia coli, Klebsiella pne
Pseudomonas aeruginosa, Proteus sp and Salmonella spp. A total of 500 clinical isolates 
were screened phenotyphically using double discs synergy test. Confirmatory tests were 
performed among the suspeced isolates according to the Clinical and Labo
Institutes guidelines (CLSI). A total of 13 antibiotic discs were used for sensitivity test 
including: Amoxicillin/clavulanic acid, ceffazidime, cefepime, cepatozime, cefuruxime, 
imipenem, meropenem, ciprofloxacin, genetamicin, levoflaxacin
and ofloxacin. Nine antibiotic discs were used on lactose fermenters and seven antibiotics 
were used on non–lactose fermenters. The result of the prevalence of class D oxa β
lactamases producing bacteria among the clinical isol
clinical isolates were confirmed positive for class D oxa Beta lactamases production with the 
highest prevalence in E. coli (37.88%) and absent in K. oxytoca. The isolates producing this 
enzyme were sourced mainly from uri
susceptibility profile using class D blaOxa showed that E. coli has overall resistance to 
clavulanic acid and third generation cephalosporins, with high susceptibility profile to 
tigercycline. (52.0%) and nitrofuranton (49.00%). 
susceptibility with tigercyclin and Nitrofuranton (56.7% and 56.4% respectively). The most 
active agents against non–lactose fermenters were meropenem, tigercycline and 
levofloxacin. The data highlight
bla OXA among the Gram –negative bacterial isolates in hospitals from Kano metropolis. The 
attention of the authorities and healthcare sectors is needed urgently towards the rising 
spate and widespread resistance due to class D oxa βlactamases so as to device a method to 
curb this threatening trend.  
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developed by bacterial species to confer 
resistance to antibiotics is their ability to 
produce class D oxa β-lactamases enzymes. 
Beta-lactamases are enzymes produced mostly 
by Gram-negative bacteria. They 
responsible for resistance to β
antibiotics by organisms possessing them (Bush 
et al., 1995). They are among the penicillinases 
that hydrolyze oxacillin and cloxacillin and are 
poorly inhibited by clavulamic acid (Poire
al., 2004).  
Since their discovery in Turkey in 2004 (Carrer 
et al., 2010), OXA β-lactamases have spread to 
Europe, the Middle East and Africa (Egypt and 
Senegal). They are responsible for 5
outbreak of nosocomial infections in intensive 
care unit, burn, oncology and neonatal units 
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Poor hygienic practices, indiscriminate use of 
antibiotics as well as lack of monitoring of 
microbial drug resistance has created suitable 
condition for the emergence and controllable 
spread of these enzymes in Nigeria (Arzai and 
Adamu, 2008). There is therefore an urgent 
need to reduce cost of point of-care diagnostics 
(Carrer et al., 2010). 
In view of the considerable medical significance 
of this wide spread class of enzymes, this 
research seeks to detect the presence of OXA 
class D β-lactamases among Gram-negative 
clinical bacterial isolates in Kano metropolis 
and to determine their antibiotic susceptibility 
profile. 
 
MATERIALS AND METHODS 
Sample Collection  
Ethical approval to collect samples for the 
study was obtained from Ethical Committee of 
the Aminu Kano Teaching Hospital (AKTH), 
Kano. A total of 500 clinical Gram-negative 
bacterial isolates were collected from the 
Aminu Kano Teaching Hospital (AKTH), Kano, 
Murtala Muhammad Specialists Hospital (MMSH) 
and Muhammad Abdullahi Wase Specialists 
Hospital (MAWSH) Kano. The clinic number, 
type of specimen, sex and age of the patients 
were documented. The isolates include; 
Escherichia coli, Klebsiella pneumoniae, 
Klebsiella oxytoca, Proteus mirabilis, Proteus 
vulgaris, Pseudomanas aeruginosa, Salmonella 
typhi and  .Salmonella paratyphi. The isolates 
were obtained from different clinical samples 
(wound, ear, vaginal swabs, blood, cerebro-
spinal fluid, urine, sputum and stool). They 
were identified by using Gram staining, 
MacConkey and Chocolate agar, swarming 
activity and confirmed with Microbact 12E 
Identification kit (Oxoid Ltd. Basingstoke, 
Hants, UK).    
Antibiotic susceptibility test   
All the clinical isolates collected were tested 
for potential class D blaOxa production as 
presumptive tests using the Cefpodoxime (10µg) 
and the Ceftriaxone (30µg) antibiotic discs. All 
the isolates suspected of class D oxa β-
lactamases production in the presumptive test 
were furthered confirmed using the double 
discs synergy according to Cheesbrough (2010). 
The antimicrobial discs used are oxacillin 
(10µg), cloxacillin (10µ), the amoxicillin–
clavulanic acid (30µg), ceftazidine (30µg), and 
cefepime (30µg) (Oxoid England). Antimicrobial 
susceptibility testing was performed on the 
isolates that produced class D blaoxa enzymes 
using Clinical and Laboratory Standard Institute 
(CLSI, 2012) protocol. A total of 13 different 
antibiotics were used, these are: 
Amoxicillin/clavulanic acid (30µg), ceffazidime 
(30µg), cefepime (30µg), cepatozime (30µg), 
cefuruxime (30 µg), imipenem (10 µg), 
meropenem (10 µg), ciprofloxacin (5 µg), 
genetamicin (10 µg), levoflaxacin (5µg), 
nitrofuranton (300 µg), tigercyline (15 µg) and 
ofloxacin (5µg). Amoxicillin/clavulanic acid, 
ceftazidime, cefatoxime, cefuroxime, 
ciprofloxacin, gentamicin, nitrofuraton, 
ofloxacin, and tigercyline were tested on 
lactose-fermentative bacteria while imipenem, 
meropenem, levofloxacin, cefepime, 
ceftazime, tigercyline, and 
Amoxicillin/clavulanic acid were tested on non-
lactose fermentative bacteria. The control and 
test plates were examined to ensure confluent 
growth (Cheessbrough, 2010). The plates were 
incubated over night at 35°C. The inhibition 
zone diameters around the disks were 
measured and interpreted according to the CLSI 
(2012) guideline. The data obtained were 
analyzed in frequency and percentage tables.  
 
RESULTS 
The result obtained for the severity of class D 
Oxa β-lactamases among the clinical isolates 
obtained in Kano is presented in Table 1. The 
result showed that 58.40% of the isolates 
obtained from the three hospitals from Kano 
produce class D oxa β-lactamases. However, E. 
coli has the highest prevalence of species 
producing class D Oxa β-lactamases (34.25%) 
while P. vulgaris has the least prevalence of 
Beta-lactamases producers (0.34%).  
Similarly, the result from the CSLI test (Table 
2) indicated that 26.40% of the clinical isolates 
obtained from the three hospitals in Kano were 
confirmed to produce class D oxa Beta 
lactamases. More so, the highest prevalence 
was found in E. coli (37.88%) while the enzyme 
production was found to be absent in K. 
oxytoca. 
Furthermore, most of the β-lactamases 
producing bacteria (Table 3) were sourced from 
either urine (55.17%) or wound swabs (26.44%). 
However, non of the isolates collected from 
cerebro-spinal fluids and stool were found to be 
β-lactamases producers. 
More so, the highest prevalence of Beta 
lactamases producing bacteria (Table 4) were 
obtained from the samples obtained from AKTH 
(62.50%) while the least was found in samples 
from MAWSH (5.56%) 
However, the antibiotic susceptibility profile of 
Class D OXA β-lactamases among lactose 
fermenters was shown in Table 5.  
The result showed that, E. coli showed overall 
resistance to amoxycillin-clavulanic acid, 
agumentin and ceptazidime. It was also 
resistant to cefuroxime and ciprofloxacin, 
gentamacin and with high susceptibility profile 
with tigercyclin (52.0%) and nitrofuranton 
(49.00%).
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K. pneumoniae has the highest susceptibility 
with tigercyclin and Nitrofuranton (56.7% and 
56.4% respectively).  
Similarly, the result for the antibiotic 
susceptibility profile of Class D OXA β-
lactamases among non-lactose fermenters is 
presented in Table 6. The result showed that, 
Levofloxacin has the highest susceptibility in 
Proteus spp (20.6%) followed by meropenem 
with (18.1%) and leftazidine has the least 
susceptibility profile. In Psudomonas aeruginosa 
Tigenocline and meropenem have the highest 
susceptibility of 7.1% each. Furthermore, P. 
aeruginosa was resistance to Amoxyclavulanic 
acid. However, Salmonella spp have the highest 
susceptibility rates with impenum, meropenem 
and tigercycline; with no MIC values with 
cepfime, feftazidime and amoxiclav.   
 
Table 1: Occurrence of class D OXA β-lactamases based on severity Kano 
Bacterial Species No. of Screened Isolates No. of Isolates Positive Prevalence(%) 
E. coli 187  100 (53.48%) 34.25 
K.pneumoniae 130 78 (60.00%) 26.71 
K. oxytoca 3 2 (66.67%) 0.69 
P. mirabilis 87 66 (75.86%) 22.60 
P. vulgaris 29 1 (3.45%) 0.34 
P. aeruginosa 56 38 (67.86%) 13.01 
S. paratyphi 2 2 (100.00%) 0.69 
S. typhi 6 5 (83.33%) 1.71 
TOTAL 500 292 (58.40%) 100 
Standard Error; 14.18,  Standard Deviation: 40.10   Mean: 36.5  
 
Table 2;  Prevalence of Class D β-lactamases Producing Bacteria based on CLSI 
Bacterial Species No of Isolates Screened No of Isolates Confirmed Positive Prevalence (%) 
E. coli 187 50 (26.74%) 37.88 
K. pneumonia 130 34 (26.15%) 25.76 
K. oxytoca 3 0 (0.00%) 0.00 
P. mirabilis 87 20 (22.99%) 15.16 
P. vulgaris 29 7 (24.14%) 5.30 
P. aeruginosa 56 14 (25.00%) 10.60 
S. paratyphi 2 2 (100.00%) 1.52 
S. typhi 6 5 (83.33%) 3.78 
TOTAL 500 132 (26.40%) 100 
Standard  Error  : 6.19,   Standard Deviation: 17.53, Mean: 16.5 
 
Table 3: Distribution of Class D Oxa β-Lactamase producing bacteria from Sources 
S/N Sources of Bacterial Species No of Isolates Producing Oxa D Prevalence (%) 
1 Urine 96 55.17 
2 Catherter tip 10 5.75 
3 Wound swab 46 26.44 
4 Ear swab 00 0.00 
5 High virginal swab 3 1.72 
6 Blood 18 10.35 
7 Cerebro spinal fluid 00 0.00 
8 Stool 0 0.00 
9 Sputum 1 0.57 
 TOTAL 174 100 
Standard Error:   10.80,  Standard deviation: 32.41  Mean: 19.33 
 
Table 4: Prevalence of Class D OXA β-lactamase isolates producers Among Hospitals  
Hospitals No of Isolates Screened No of Isolate Positive % Prevalence (%) 
AKTH 311 180 (57.88%) 62.50 
MMSH 169 92 (54.44%) 31.94 
MAWSH 20 16 (80.00%) 5.56 
TOTAL 500 288 (57.60%) 100 




Special Conference Edition, November, 2018 
 






 Sen Inter Res Res% Sen Inter Res Res % 
AUG 0.00 0.00 100 0.00 0.00 0.00 78 0.00 
CAZ 5 12 83 5.0 1 10 69 1.3 
CPR 7 30 63 7.0 4 26 50 5.1 
CRX 1 3 96 1.0 4 8 68 5.1 
CXM 0.00 0.00 100 0.00 1 0.00 79 1.3 
Gen 45 5 50 45.0 30 2 48 38.5 
NIT 49 24 27 49.0 44 2 34 56.4 
OFL 30 8 62 30.0 29 7 44 37.2 
TGC 52 26 22 52.0 45 21 14 57.7 
Total 189 108 203 189 158 76  202.6 
Key: Sen = Sensitive   Inter = Intermediate  Res = Resistance  Res % = Resistance 
Percentage 









 Sen Inter Res Res% Sen Inter Res Res % Sen Inter Res Res % 
AUG 0.00 0.00 116 0.00 0.00 0.00 56 0.00 0.00 0.00 7 0.00 
CAZ 2 10 104 1.7 2 2 52 3.6 0.00 1 6 0.00 
FEP 13 9 94 11.2 3 1 52 5.4 0.00 --- 7 0.00 
IPM 7 13 96 6.0 1 6 49 1.8 4 1 2 57.1 
LEV 24 10 82 20.6 3 1 52 5.4 3 --- 4 42.8 
MEM 21 18 72 18.1 4 3 49 7.1 5 1 1 71.4 
TCG 39 13 64 33.6 4 5 47 7.1 `5 2 --- 71.4 
Total 106 73 512 91.2 17 18 301 30.4 17 5 20 242.7 




Several studies on the prevalence of Class D 
Oxa Beta lactamases were conducted in 
different parts of the world among clinical 
isolates. This study was among the first 
performed in Nigeria. The study revealed high 
incidence of this resistance conferring enzyme 
among the studied clinical isolates with E. coli 
as the most predominant Class D Oxa Beta-
lactamases production. This finding is 
conformity with the findings of Aibinu et al. 
(2003) who reported highest prevalence of 
Extended Spectrum of Beta Lactamases 
production of 20.8% in E. coli in Lagos Nigeria. 
Similar result was reported by Yasmin (2012) 
among some clinical isolates from Nigeria. 
However, this finding is contrary to that of 
Yusuf et al. (2013) who reported Shiegella spp 
as the most predominant Beta-lactamases 
producer among clinical isolates from some 
tertiary health care centers in Kano.   
The distribution of β-lactamases among clinical 
specimens indicated highest prevalence from 
the samples isolated from urine. This finding is 
in agreement with the work of Doughari and 
Akafa (2009), who reported a higher prevalence 
rate of 91% β-lactamase in urine, Iroha et al. 
(2010) who reported high prevalence of 60.3% 
in urine and Osazuwa and Osazuwa (2011) who 
also found that ESBLs prevalence was high in 
urine (61.4%). The high prevalence of β-
lactamses in urine may probably be related to 
factors like extreme age, female gender, sexual 
activity, contraception, pregnancy, urinary 
tract obstruction, neurological dysfunction, 
antimicrobial use and poor hand washing 
techniques among health care practitioners, 
which are some of the factors that can 
predispose one to urinary tract infection (UTI) 
development as reported by Eze et al. (2015) 
from Nsuka, Nigeria. 
High resistance to β-lactam was shown in β-
lactamase producers in clinical isolates. This is 
because β-lactamases producers have enzymes 
that relax the active site of the antibiotics. The 
high resistance to antibiotics reported by this 
study conforms to the earlier reports by Aibinu 
et al. (2003) who discovered that all ESBLs 
producing Enterobacter spp were resistant to 
ciprofloxacin. Paterson et al. (2000) had 
reported that globally, 18% of all ESBLs 
producers were resistant to ciprofloxacin. More 
so, Eze et al. (2015) reported ESBLs producing 
E. coli and Klebsiella spp in Nsukka, Enugu 
State as resistant to ciprofloxacin. 
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This means that the resistance phenomenon is 
on the increase. This increasing resistance to 
several antimicrobial drugs may be due to 
inappropriate use of antimicrobial drugs (over 
use, misuse, suboptimal dosage and non-
compliance with the treatment duration) which 
leads to selection pressure. This abuse of 
antibiotics is reported by Muhammad et al. 
(2010) have impressed a selective pressure that 
causes discovery of more resistant bacteria. 
The resistance by β-lactamase producers was 
also shown against imipenem. This is in 
agreement with the work of Asma et al. (2014).  
The resistance can also be attributed to the 
organisms’ ability to encode multiple antibiotic 
resistance genes as reported by Perez et al. 
(2007). In the present study, ampicillin, 
amoxyclauve were found to show total 
resistance. This finding is in conformity with 
the work of Ullah et al. (2009) and Sasirekha et 
al. (2010) who individually reported similar 
findings.  Recent studies by Heritier et al. 
(2005) revealed that both resistant genes exist 
in carbapenem–resistant clinical isolates of 
Acinetobacter spp from various continents and 
for even more than 10 years in some countries. 
In another study by Coelho et al. (2006) in 
Portugal showed that the blaOXA gene  exists in 
the gram–negative enterobacteriaceae and 
Pseudomonas spp in United Kingdom, South 
Africa and Brazil. This is in conformity with the 
finding of Alber et al. (2004) as blaoxa gene 
was found in E. coli, K. pneumoniae, 
Salmonella spp, Proteus spp and Shigella spp. 
In this study, E. coli is found to be totally 
resistance to agumentin, ceptazidime, 
cefuroxime and  ciprofloxacin. This is in line 
with the work of Adrian et al. (2007) in South 
Africa where E. coli isolates were reported to 
be resistants to third generation 
cephalosporins, quinolones and β-lactam 
antibiotics. The susceptibility test conducted 
on lactose fermentative bacteria showed that 
tigercycline was the most active drug against 
lactose fermentative bacteria. This can 
probably be due to stearic hindrance from its 9-
glyclyamide structure and avoid ribosomal 
binding, therefore is unaffected by ribosomal 
alteration and efflux pumps as reported by 
Adrian et al. (2007). The high level of 
resistance could be due to the ability of the 
bacteria to harbor more than one multiple 
antibiotics resistance genes such as gene for 
production of “efflux pumps” and antibiotic 
altering enzyme. 
CONCLUSION  
It was concluded that Class D Oxa β-lactamases 
producing bacteria exist among the clinical 
isolates obtained in Kano with E. coli having the 
highest prevalence. However, the sensitivity 
test indicated that the organisms were highly 
resistant to the antibiotics used. This showed 
that the presence of blaOXA gene is responsible 
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